Trending...
- Massachusetts: Baker-Polito Administration Launches COVID-19 Vaccine CDC Pharmacy Partnership - Phase 1, Expands Vaccine Locations & Names Fenway Park as Mass Vaccination Site
- Boston: A message from Commissioner McCosh: Inauguration event accessibility
- The Atlas Group adds Corbin Raines to their list of professional property managers
BOSTON, Dec. 21, 2020 /PRNewswire/ -- Emulate, Inc., a leading provider of advanced in vitro models, today unveiled the Emulate Brain-Chip, which is designed for neuroscience researchers investigating neuroinflammatory disease and for drug developers seeking to improve drug discovery for neurodegenerative diseases such as Alzheimer's and Parkinson's. The comprehensive model incorporates cells from the human brain, including the blood-brain barrier, in a dynamic microenvironment which enables cell-cell interaction.
Emulate Organ-Chips, including the Brain-Chip, are designed to enable researchers to investigate the safety and efficacy of therapeutic treatments in development, in order to reduce the high drug development failure rates that result from a poor understanding of drug mechanism of action, toxicity, pharmacokinetic profile, or overall applicability and translation of animal and in vitro models used in preclinical research.
"The global burden of neurodegenerative diseases is high, yet despite billions of dollars invested in developing new treatments, biopharmaceutical companies are struggling to develop successful therapies," said Lorna Ewart, EVP, Science Liaison of Emulate. "Better modeling of the human brain can help researchers and pharmaceutical companies develop new understandings of the mechanisms of neuroinflammatory disease, the inner workings of the blood-brain barrier, drug toxicity, and drug effectiveness, which we hope can streamline the drug development process and bring safer, more effective treatments for neurodegenerative disease to market faster."
More on Boston Chron
The Emulate Brain-Chip is a comprehensive model of a neurovascular unit, including the blood-brain barrier, containing five human primary and induced pluripotent stem cell-derived (iPSC) cell types (neurons, microglia, astrocytes, pericytes, and brain microvascular endothelial cells) in a dynamic, tunable microenvironment, resulting in in vivo-like gene expression. The incorporation of microglia allows researchers to reproduce key features of neuroinflammation— including microglial activation, astrogliosis, and pro-inflammatory cytokines—presenting a more human-relevant model for evaluating new therapeutics than animal testing or conventional cell culture.
The development of the Emulate Brain-Chip was partially supported by grant funding received from the U.S. National Institutes of Health and the Michael J. Fox Foundation in 2018.
Emulate will be presenting a poster on the development of the Brain-Chip as a model to study neuroinflammatory diseases at the Society for Neuroscience next month. For more information, visit human.emulatebio.com/sfn.
About Emulate, Inc.
Emulate Inc. is a privately held company that creates advanced in vitro models for understanding how diseases, medicines, chemicals, and foods affect human health. Our lab-ready Human Emulation System® includes three components: Zoë® Culture Module, Organ-Chips, and analytical software applications. The platform provides a window into the inner workings of human biology and disease—offering researchers a new technology designed to predict human response with greater precision and detail than conventional cell culture or animal-based experimental testing. Each of the Emulate proprietary Organ-Chip models—including the liver, intestine, and kidney—contains tiny hollow channels lined with tens of thousands of living human cells and tissues and is approximately the size of an AA battery. An Organ-Chip is a living, microengineered environment that recreates the natural physiology and mechanical forces that cells experience within the human body. Our founding team pioneered the Organs-on-Chips technology at the Wyss Institute for Biologically Inspired Engineering at Harvard University. Emulate holds the worldwide exclusive license from Harvard University to a robust and broad intellectual property portfolio for the Organs-on-Chips technology and related systems. For more information, please visit emulatebio.com.
More on Boston Chron
SOURCE Emulate
Emulate Organ-Chips, including the Brain-Chip, are designed to enable researchers to investigate the safety and efficacy of therapeutic treatments in development, in order to reduce the high drug development failure rates that result from a poor understanding of drug mechanism of action, toxicity, pharmacokinetic profile, or overall applicability and translation of animal and in vitro models used in preclinical research.
"The global burden of neurodegenerative diseases is high, yet despite billions of dollars invested in developing new treatments, biopharmaceutical companies are struggling to develop successful therapies," said Lorna Ewart, EVP, Science Liaison of Emulate. "Better modeling of the human brain can help researchers and pharmaceutical companies develop new understandings of the mechanisms of neuroinflammatory disease, the inner workings of the blood-brain barrier, drug toxicity, and drug effectiveness, which we hope can streamline the drug development process and bring safer, more effective treatments for neurodegenerative disease to market faster."
More on Boston Chron
- Congressional Medal of Honor Society will host 2021 convention in Boston
- Boston: Update on the Ronan Park Well
- Avery Design Announces CXL™ 2.0 VIP
- Nova Biomedical FLEX2 Cell Culture Analyzer Adds Sample Retain Capability
- Kaizen Finance Launches Staking to Foster the Widespread Adoption of DeFi
The Emulate Brain-Chip is a comprehensive model of a neurovascular unit, including the blood-brain barrier, containing five human primary and induced pluripotent stem cell-derived (iPSC) cell types (neurons, microglia, astrocytes, pericytes, and brain microvascular endothelial cells) in a dynamic, tunable microenvironment, resulting in in vivo-like gene expression. The incorporation of microglia allows researchers to reproduce key features of neuroinflammation— including microglial activation, astrogliosis, and pro-inflammatory cytokines—presenting a more human-relevant model for evaluating new therapeutics than animal testing or conventional cell culture.
The development of the Emulate Brain-Chip was partially supported by grant funding received from the U.S. National Institutes of Health and the Michael J. Fox Foundation in 2018.
Emulate will be presenting a poster on the development of the Brain-Chip as a model to study neuroinflammatory diseases at the Society for Neuroscience next month. For more information, visit human.emulatebio.com/sfn.
About Emulate, Inc.
Emulate Inc. is a privately held company that creates advanced in vitro models for understanding how diseases, medicines, chemicals, and foods affect human health. Our lab-ready Human Emulation System® includes three components: Zoë® Culture Module, Organ-Chips, and analytical software applications. The platform provides a window into the inner workings of human biology and disease—offering researchers a new technology designed to predict human response with greater precision and detail than conventional cell culture or animal-based experimental testing. Each of the Emulate proprietary Organ-Chip models—including the liver, intestine, and kidney—contains tiny hollow channels lined with tens of thousands of living human cells and tissues and is approximately the size of an AA battery. An Organ-Chip is a living, microengineered environment that recreates the natural physiology and mechanical forces that cells experience within the human body. Our founding team pioneered the Organs-on-Chips technology at the Wyss Institute for Biologically Inspired Engineering at Harvard University. Emulate holds the worldwide exclusive license from Harvard University to a robust and broad intellectual property portfolio for the Organs-on-Chips technology and related systems. For more information, please visit emulatebio.com.
More on Boston Chron
- Ismail Sirdah Describes the Best Practices for Holding Corporate Events
- MDAdvantage Appoints Pete Cammarano to Board of Directors
- CEO Coaching International Congratulates Client Orion Energy on Successful Capital Partnerships
- expEDIum Direct Pay®, seamless online payment added to iTech's expEDIum Medical Billing®
- Office Properties Income Trust Fourth Quarter 2020 Conference Call Scheduled for Friday, February 19th
SOURCE Emulate
Filed Under: Business
0 Comments
Latest on Boston Chron
- Pro Golfer Kamaiu Johnson Joins Cambridge Mobile Telematics as Brand Ambassador
- Empirix Helps CEHE Confidently Migrate to Five9 Cloud-Based Contact Center Software USA - English USA - English
- Northway Biotech Opens New Biopharmaceutical Manufacturing Facility in Greater Boston Area
- Manulife Investment Management announces new managing director of institutional distribution, southeast region
- Boston: Meet some of this year's Opportunity Fund grantees
- City Streaming TV, a Streaming Television Inc Network Launches, bringing Community and Faith Leaders into local TV's, At No Cost
- Perini Management Services, Inc. Announces Two Federal Contracts Collectively Valued at $66.9 Million
- "GLORY of HISTORY" Hip-Hop Music Video Looks At Voter's Choice
- BoatDealers.ca Surges with Record Traffic in 2020
- CoVerified Announces Partnership with Mirimus for Nationwide K-12 Pooled Saliva COVID-19 Testing Program
- Reify Health Announces Global Expansion of StudyTeam to Over 2,700 Clinical Research Sites
- 'Aesthetic Institute of Massachusetts' Announces Rebranding to 'Aesthetic Mentor'
- OCC Adopts Final Rule Requiring Large Banks to Provide Fair Access to Banking Services
- New GCI Study On Gynecologic Cancers in Brazil Finds Most Patients Present With Advanced Disease
- The Antenna Company Announces Venture Debt Financing Agreement with Brabant Development Agency (BOM)
- Haemonetics To Acquire Cardiva Medical, Inc. To Expand Hospital Portfolio
- Cohere Capital Completes Strategic Growth Investment in CCS, a Leading Digital Brand and E-Commerce Retailer
- Syros Announces Pricing of $75.6 Million Public Offering of Common Stock
- Code18 Interactive Launches New Websites for Balmex and Balmex Adult
- LabMinds Successfully Receives Approval for Use in a GMP Certified Laboratory.